9 Einträge von 19 mit monoclonal light
www.cslbehring.ch
Datum der Indexierung 13.03.2021 22:42:48
erkannte Namen Alex Gertsch | Gérard Jenni | Georg Ptak | Patricia Stutz | Corona Ladensterben |
weitere Namen in www.cslbehring.ch 5
Subdomain:
extern (outbound) Link/Domain 0 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description pdf
Kombination Keywords haemophilia from | phase japan | specialty market | study rviii | with immunoglobulins | patients clinical | products prophylaxis | bleeding breakthrough | rix-fp development | global medicines |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
monoclonal antibody FXIIa MAb Specialty 61 CSL312 Development Plan – HAE Therapy • New molecule and target – potential benefit: o In refractive patients o For HAE types I, II and III as well as ACE inhibitor induced oedema o For subcutaneous delivery lights Andrew Cuthbertson • Research & Early Development Andrew Nash • Immunoglobulins & Specialty Products • Clinical Development Charmaine Gittleson • Commercial Opportunities Bob Repella • Q&A Break • Coagulation/Haemophilia •
Text Inhalt Text aus URL
Log Metriken 446267
erkannte Namen Alex Gertsch | Gérard Jenni | Georg Ptak | Patricia Stutz | Corona Ladensterben |
weitere Namen in www.cslbehring.ch 5
Subdomain:
extern (outbound) Link/Domain 0 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description pdf
Kombination Keywords haemophilia from | phase japan | specialty market | study rviii | with immunoglobulins | patients clinical | products prophylaxis | bleeding breakthrough | rix-fp development | global medicines |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
monoclonal antibody FXIIa MAb Specialty 61 CSL312 Development Plan – HAE Therapy • New molecule and target – potential benefit: o In refractive patients o For HAE types I, II and III as well as ACE inhibitor induced oedema o For subcutaneous delivery lights Andrew Cuthbertson • Research & Early Development Andrew Nash • Immunoglobulins & Specialty Products • Clinical Development Charmaine Gittleson • Commercial Opportunities Bob Repella • Q&A Break • Coagulation/Haemophilia •
Text Inhalt Text aus URL
Log Metriken 446267
clinicalodyssey.com
Datum der Indexierung
erkannte Namen Ann Oncol |
Subdomain:
extern (outbound) Link/Domain 2 in .clinicalodyssey.com
intern (inbound) Link/Domain .clinicalodyssey.com
Alle Links in alle Links in .clinicalodyssey.com
Kombination Keywords patients present | bone treatment | with protein | myeloma syndrome | plasma hypercalcemia | monoclonal light | serum these | cell renal | multiple marrow | have disease |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
monoclonal immunoglobulin (IgG, IgM, IgA, or rarely, IgE or IgD) or light chain protein (kappa or lambda). MM accounts for 1% of all cancers and ~10% of all hematologic malignancies. It is twice more common in blacks than whites, with a slight male p light chain protein (kappa or lambda). MM accounts for 1% of all cancers and ~10% of all hematologic malignancies. It is twice more common in blacks than whites, with a slight male predominance. Median survival is 5 to 7 years. Ad
Text Inhalt Text aus URL
Log Metriken 1038118
erkannte Namen Ann Oncol |
Subdomain:
extern (outbound) Link/Domain 2 in .clinicalodyssey.com
intern (inbound) Link/Domain .clinicalodyssey.com
Alle Links in alle Links in .clinicalodyssey.com
Kombination Keywords patients present | bone treatment | with protein | myeloma syndrome | plasma hypercalcemia | monoclonal light | serum these | cell renal | multiple marrow | have disease |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
monoclonal immunoglobulin (IgG, IgM, IgA, or rarely, IgE or IgD) or light chain protein (kappa or lambda). MM accounts for 1% of all cancers and ~10% of all hematologic malignancies. It is twice more common in blacks than whites, with a slight male p light chain protein (kappa or lambda). MM accounts for 1% of all cancers and ~10% of all hematologic malignancies. It is twice more common in blacks than whites, with a slight male predominance. Median survival is 5 to 7 years. Ad
Text Inhalt Text aus URL
Log Metriken 1038118
clinicalodyssey.com
Datum der Indexierung 07.11.2021 20:19:34
erkannte Namen Ann Oncol |
Subdomain:
extern (outbound) Link/Domain 2 in .clinicalodyssey.com
intern (inbound) Link/Domain .clinicalodyssey.com
Alle Links in alle Links in .clinicalodyssey.com
Kombination Keywords patients syndrome | bone protein | myeloma treatment | plasma cells | with hypercalcemia | serum light | monoclonal these | multiple renal | cell marrow | have disease |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
monoclonal immunoglobulin (IgG, IgM, IgA, or rarely, IgE or IgD) or light chain protein (kappa or lambda). MM accounts for 1% of all cancers and ~10% of all hematologic malignancies. It is twice more common in blacks than whites, with a slight male p light chain protein (kappa or lambda). MM accounts for 1% of all cancers and ~10% of all hematologic malignancies. It is twice more common in blacks than whites, with a slight male predominance. Median survival is 5 to 7 years. Ad
Text Inhalt Text aus URL
Log Metriken 1038118
erkannte Namen Ann Oncol |
Subdomain:
extern (outbound) Link/Domain 2 in .clinicalodyssey.com
intern (inbound) Link/Domain .clinicalodyssey.com
Alle Links in alle Links in .clinicalodyssey.com
Kombination Keywords patients syndrome | bone protein | myeloma treatment | plasma cells | with hypercalcemia | serum light | monoclonal these | multiple renal | cell marrow | have disease |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
monoclonal immunoglobulin (IgG, IgM, IgA, or rarely, IgE or IgD) or light chain protein (kappa or lambda). MM accounts for 1% of all cancers and ~10% of all hematologic malignancies. It is twice more common in blacks than whites, with a slight male p light chain protein (kappa or lambda). MM accounts for 1% of all cancers and ~10% of all hematologic malignancies. It is twice more common in blacks than whites, with a slight male predominance. Median survival is 5 to 7 years. Ad
Text Inhalt Text aus URL
Log Metriken 1038118
clinicalodyssey.com
Datum der Indexierung
Subdomain:
extern (outbound) Link/Domain 2 in .clinicalodyssey.com
intern (inbound) Link/Domain .clinicalodyssey.com
Alle Links in alle Links in .clinicalodyssey.com
Kombination Keywords symptoms medicine | clinical patients | bone pain | features odyssey | years joyworks | hypercalcemia myeloma | present multiple | your medical | hyperviscosity syndrome | subscribe about |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
monoclonal immunoglobulin (IgG, IgM, IgA, or rarely, IgE or IgD) or light chain protein (kappa or lambda). MM accounts for 1% of all cancers and ~10% of all hematologic malignancies. It is twice more common in blacks than whites, with a slight male p light chain protein (kappa or lambda). MM accounts for 1% of all cancers and ~10% of all hematologic malignancies. It is twice more common in blacks than whites, with a slight male predominance. Median survival is 5 to 7 years. Ad
Text Inhalt Text aus URL
Log Metriken 1038118
Subdomain:
extern (outbound) Link/Domain 2 in .clinicalodyssey.com
intern (inbound) Link/Domain .clinicalodyssey.com
Alle Links in alle Links in .clinicalodyssey.com
Kombination Keywords symptoms medicine | clinical patients | bone pain | features odyssey | years joyworks | hypercalcemia myeloma | present multiple | your medical | hyperviscosity syndrome | subscribe about |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
monoclonal immunoglobulin (IgG, IgM, IgA, or rarely, IgE or IgD) or light chain protein (kappa or lambda). MM accounts for 1% of all cancers and ~10% of all hematologic malignancies. It is twice more common in blacks than whites, with a slight male p light chain protein (kappa or lambda). MM accounts for 1% of all cancers and ~10% of all hematologic malignancies. It is twice more common in blacks than whites, with a slight male predominance. Median survival is 5 to 7 years. Ad
Text Inhalt Text aus URL
Log Metriken 1038118
www.medicaljoyworks.com
Datum der Indexierung
erkannte Namen Ann Oncol |
Subdomain:
extern (outbound) Link/Domain 2 in www.medicaljoyworks.com
intern (inbound) Link/Domain www.medicaljoyworks.com
Alle Links in alle Links in www.medicaljoyworks.com
HTML Description Bruised References
Kombination Keywords with treatment | macroglobulinemia waldenström | from disease | september patients | available note | viewed this | online clinical | bone that | monoclonal waldenstrom | lymphoma marrow |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
monoclonal gammopathies. A complete blood count and peripheral smear are essential first-line investigations; the former reveals the presence of anemia and thrombocytopenia, with a lymphocyte predominant leukocytosis; the latter shows rouleaux format light male predominance. No definite etiological agent has been identified; however, environmental, genetic and viral factors are known to be associated with the condition. Note also that IgM monoclonal gammopathies of undetermine
Text Inhalt Text aus URL
Log Metriken 646363
erkannte Namen Ann Oncol |
Subdomain:
extern (outbound) Link/Domain 2 in www.medicaljoyworks.com
intern (inbound) Link/Domain www.medicaljoyworks.com
Alle Links in alle Links in www.medicaljoyworks.com
HTML Description Bruised References
Kombination Keywords with treatment | macroglobulinemia waldenström | from disease | september patients | available note | viewed this | online clinical | bone that | monoclonal waldenstrom | lymphoma marrow |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
monoclonal gammopathies. A complete blood count and peripheral smear are essential first-line investigations; the former reveals the presence of anemia and thrombocytopenia, with a lymphocyte predominant leukocytosis; the latter shows rouleaux format light male predominance. No definite etiological agent has been identified; however, environmental, genetic and viral factors are known to be associated with the condition. Note also that IgM monoclonal gammopathies of undetermine
Text Inhalt Text aus URL
Log Metriken 646363
clinicalodyssey.com
Datum der Indexierung
Subdomain:
extern (outbound) Link/Domain 2 in .clinicalodyssey.com
intern (inbound) Link/Domain .clinicalodyssey.com
Alle Links in alle Links in .clinicalodyssey.com
Kombination Keywords clinical persons | your joyworks | symptoms subscribe | present from | about multiple | bone myeloma | hypercalcemia medical | hyperviscosity medicine | odyssey syndrome | features years |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
monoclonal immunoglobulin (IgG, IgM, IgA, or rarely, IgE or IgD) or light chain protein (kappa or lambda). MM accounts for 1% of all cancers and ~10% of all hematologic malignancies. It is twice more common in persons of African descent than in Cauca light chain protein (kappa or lambda). MM accounts for 1% of all cancers and ~10% of all hematologic malignancies. It is twice more common in persons of African descent than in Caucasians, with a slight male predominance. Median s
Text Inhalt Text aus URL
Log Metriken 1038118
Subdomain:
extern (outbound) Link/Domain 2 in .clinicalodyssey.com
intern (inbound) Link/Domain .clinicalodyssey.com
Alle Links in alle Links in .clinicalodyssey.com
Kombination Keywords clinical persons | your joyworks | symptoms subscribe | present from | about multiple | bone myeloma | hypercalcemia medical | hyperviscosity medicine | odyssey syndrome | features years |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
monoclonal immunoglobulin (IgG, IgM, IgA, or rarely, IgE or IgD) or light chain protein (kappa or lambda). MM accounts for 1% of all cancers and ~10% of all hematologic malignancies. It is twice more common in persons of African descent than in Cauca light chain protein (kappa or lambda). MM accounts for 1% of all cancers and ~10% of all hematologic malignancies. It is twice more common in persons of African descent than in Caucasians, with a slight male predominance. Median s
Text Inhalt Text aus URL
Log Metriken 1038118
clinicalodyssey.com
Datum der Indexierung
Subdomain:
extern (outbound) Link/Domain 2 in .clinicalodyssey.com
intern (inbound) Link/Domain .clinicalodyssey.com
Alle Links in alle Links in .clinicalodyssey.com
Kombination Keywords cells chimeric | cell genetic | malignant t-cells | plasma patient | multiple therapies | myeloma bcma | antigen these | against with | rrmm their | from clinical |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
monoclonal proteins and free light chains. Although multiple myeloma cells tend to proliferate in and infiltrate the bone marrow, malignant cells may circulate into the peripheries. Genetic causes of multiple myeloma Multiple myeloma is often associa light chains. Although multiple myeloma cells tend to proliferate in and infiltrate the bone marrow, malignant cells may circulate into the peripheries. Genetic causes of multiple myeloma Multiple myeloma is often associated with
Text Inhalt Text aus URL
Log Metriken 1174198
Subdomain:
extern (outbound) Link/Domain 2 in .clinicalodyssey.com
intern (inbound) Link/Domain .clinicalodyssey.com
Alle Links in alle Links in .clinicalodyssey.com
Kombination Keywords cells chimeric | cell genetic | malignant t-cells | plasma patient | multiple therapies | myeloma bcma | antigen these | against with | rrmm their | from clinical |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
monoclonal proteins and free light chains. Although multiple myeloma cells tend to proliferate in and infiltrate the bone marrow, malignant cells may circulate into the peripheries. Genetic causes of multiple myeloma Multiple myeloma is often associa light chains. Although multiple myeloma cells tend to proliferate in and infiltrate the bone marrow, malignant cells may circulate into the peripheries. Genetic causes of multiple myeloma Multiple myeloma is often associated with
Text Inhalt Text aus URL
Log Metriken 1174198
clinicalodyssey.com
Datum der Indexierung
Subdomain:
extern (outbound) Link/Domain 2 in .clinicalodyssey.com
intern (inbound) Link/Domain .clinicalodyssey.com
Alle Links in alle Links in .clinicalodyssey.com
Kombination Keywords clinical persons | your joyworks | symptoms subscribe | present from | about multiple | bone myeloma | hypercalcemia medical | hyperviscosity medicine | odyssey syndrome | features years |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
monoclonal immunoglobulin (IgG, IgM, IgA, or rarely, IgE or IgD) or light chain protein (kappa or lambda). MM accounts for 1% of all cancers and ~10% of all hematologic malignancies. It is twice more common in persons of African descent than in Cauca light chain protein (kappa or lambda). MM accounts for 1% of all cancers and ~10% of all hematologic malignancies. It is twice more common in persons of African descent than in Caucasians, with a slight male predominance. Median s
Text Inhalt Text aus URL
Log Metriken 1038118
Subdomain:
extern (outbound) Link/Domain 2 in .clinicalodyssey.com
intern (inbound) Link/Domain .clinicalodyssey.com
Alle Links in alle Links in .clinicalodyssey.com
Kombination Keywords clinical persons | your joyworks | symptoms subscribe | present from | about multiple | bone myeloma | hypercalcemia medical | hyperviscosity medicine | odyssey syndrome | features years |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
monoclonal immunoglobulin (IgG, IgM, IgA, or rarely, IgE or IgD) or light chain protein (kappa or lambda). MM accounts for 1% of all cancers and ~10% of all hematologic malignancies. It is twice more common in persons of African descent than in Cauca light chain protein (kappa or lambda). MM accounts for 1% of all cancers and ~10% of all hematologic malignancies. It is twice more common in persons of African descent than in Caucasians, with a slight male predominance. Median s
Text Inhalt Text aus URL
Log Metriken 1038118
www.cslbehring.ch
Datum der Indexierung 25.04.2021 00:30:41
erkannte Namen Alex Gertsch | Gérard Jenni | Georg Ptak | Patricia Stutz | Corona Ladensterben |
weitere Namen in www.cslbehring.ch 5
Subdomain:
extern (outbound) Link/Domain 0 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description pdf
Kombination Keywords haemophilia program | phase market | specialty rviii | study immunoglobulins | products prophylaxis | patients research | with breakthrough | global medicines | development rix-fp | clinical bleeding |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
monoclonal antibody FXIIa MAb Specialty 61 CSL312 Development Plan – HAE Therapy • New molecule and target – potential benefit: o In refractive patients o For HAE types I, II and III as well as ACE inhibitor induced oedema o For subcutaneous delivery lights Andrew Cuthbertson • Research & Early Development Andrew Nash • Immunoglobulins & Specialty Products • Clinical Development Charmaine Gittleson • Commercial Opportunities Bob Repella • Q&A Break • Coagulation/Haemophilia •
Text Inhalt Text aus URL
Log Metriken 563121
erkannte Namen Alex Gertsch | Gérard Jenni | Georg Ptak | Patricia Stutz | Corona Ladensterben |
weitere Namen in www.cslbehring.ch 5
Subdomain:
extern (outbound) Link/Domain 0 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description pdf
Kombination Keywords haemophilia program | phase market | specialty rviii | study immunoglobulins | products prophylaxis | patients research | with breakthrough | global medicines | development rix-fp | clinical bleeding |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
monoclonal antibody FXIIa MAb Specialty 61 CSL312 Development Plan – HAE Therapy • New molecule and target – potential benefit: o In refractive patients o For HAE types I, II and III as well as ACE inhibitor induced oedema o For subcutaneous delivery lights Andrew Cuthbertson • Research & Early Development Andrew Nash • Immunoglobulins & Specialty Products • Clinical Development Charmaine Gittleson • Commercial Opportunities Bob Repella • Q&A Break • Coagulation/Haemophilia •
Text Inhalt Text aus URL
Log Metriken 563121